Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • DNA Repair
  • DNA, Neoplasm
  • Drug Resistance, Neoplasm
  • Eukaryotic Initiation Factor-2
  • Gene Expression Regulation, Neoplastic
  • TOR Serine-Threonine Kinases

abstract

  • Results indicated improvement in cognitive function up to 3¬†years post-treatment, but a decline at later time points and an increase in brain structure abnormalities in both groups. The findings suggest that rdWBRT and HDC-ASCT may be associated with delayed neurotoxicity in progression-free patients and underscore the need for long-term follow-up to characterize cognitive dysfunction in PCNSL patients.

publication date

  • September 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s11060-019-03257-1

PubMed ID

  • 31377920

Additional Document Info

start page

  • 553

end page

  • 562

volume

  • 144

number

  • 3